目的 研究恩替卡韦分散片的处方工艺。 方法 根据辅料相容性结果,采用正交实验法,将辅料的用量和加入方法作为考察因素,筛选出恩替卡韦分散片处方中乳糖、微晶纤维素、羧甲淀粉钠、硬脂酸镁、阿司帕坦和甜橙香精的最佳配比。 结果 确定了恩替卡韦分散片处方:乳糖 70 g ,微晶纤维素 20 g , 10% 的聚维酮溶液用量为 15 mL ,崩解剂用量为 7 g ,崩解剂加入方式为外加。 结论 所选恩替卡韦分散片的处方合理,工艺简单。
Abstract
OBJECTIVE To optimize the formulation and technology of entecavir dispersible tablets. METHODS ■Orthogonal test was used to screen the optimum proportion of lactose, MCC, carboxymethyl starch sodium, magnesium stearate, aspartame and melit-orange essence etc. The adjuvant compatibility was also observed. RESULTS According to the results of the single factor analysis and orthogonal test, the optimal condition of entecavir dispersible tablets were as follows: lactose 70 g, MCC 20 g, 10% PVP 15 mL, disintegrating agent 7 g. The disintegrating agent was extrinsic added. CONCLUSION This preparation of entecavir dispersible tablets is reasonable, and the technology is simple.
关键词
恩替卡韦 /
分散片 /
处方工艺 /
正交实验
{{custom_keyword}} /
Key words
entecavir /
dispersible tablets /
formulation and technology /
orthogonal test
{{custom_keyword}} /
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] SHERMAN M, YURDAYDIN C, SOLLANO J. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B[J]. Gastroenterology, 2006, 130(7): 2039-2049.
[2] FABIEN ZOULIM F. Entecavir: A new treatment option for chronic hepatitis B[J]. J Clin Virol, 2006, 36(1): 8-12.
[3] LI W G, YUAN J X, LI P, <>et al. A new route for synthesis of entecavir[J]. Chin Chem Lett (中国化学快报英文版) , 2006, 17 ( 7 ) : 907-910.
[4] YU H W, LI J, MENG Q H, <>et al. Clinical study of entecavir treatment in patients with subacute on chronic liver failure[J]. J Clin Hepatol, 2008, 11(6):380-382.
[5] LI L, ZHOU Y N. Cost-effectiveness analysis of three drugs in the treatment of chronic hepatitis B[J]. <>Chin J Pharmacoepidemiol( 药物流行病学杂志 ), 2008, 17(5): 340-341.
( 收稿日期 : 2009-06-10 )
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}